Skip to main content

From Suspicion to Specificity: Expanding the Diagnostic Lens in Infectious Disease

When the cause of infection remains uncertain, hybrid-capture next-generation sequencing (NGS) can help clinicians move beyond suspicion toward actionable answers.

Infectious disease diagnosis is often straightforward. Symptoms align with clinical presentation, targeted tests confirm a suspected pathogen, and treatment decisions quickly follow. But some patients do not follow the expected path.

In immunocompromised individuals, transplant recipients, oncology patients, and others at increased risk for opportunistic infections, diagnostic clues can be frustratingly incomplete. Imaging findings may be nonspecific. Symptoms may overlap with multiple conditions. Cultures can be negative, and conventional molecular tests only identify organisms they are specifically designed to detect. In these situations, clinicians may have a strong suspicion that infection is present, but limited information about the underlying cause.

Increasingly, next-generation sequencing (NGS) technologies are helping bridge that gap between suspicion and specificity.

Seeing beyond traditional diagnostic boundaries

Conventional infectious disease testing typically asks a focused question: “Is this organism present?” whileNGS asks a broader one: “What organism is present?”

This distinction can be particularly important when disease causation is unclear or when traditional testing fails to produce definitive answers. Rather than searching for a single pathogen at a time, NGS technology allows clinicians to evaluate a much broader range of potential infectious causes simultaneously.

Think of the diagnostic process as assembling a picture from scattered clues. A CT scan may suggest infection. Laboratory values may indicate inflammation. A patient’s symptoms may point toward multiple possibilities. Yet critical pieces of the puzzle often remain missing. NGS can help clinicians view the broader microbial landscape and uncover pathogens that may not have been initially suspected.

What is NeXGen™ Testing?

NeXGen™ is Eurofins Viracor’s hybrid-capture NGS platform, designed to identify clinically relevant microbial DNA from patient specimens. Unlike shotgun sequencing approaches, hybrid-capture technology uses targeted probes to enrich microbial DNA before sequencing, helping identify pathogen genetic material that may be present at low levels within a large background of human DNA.

This enrichment strategy can provide deeper coverage of organisms of interest and support the detection of pathogens that may be difficult to identify using traditional methods alone.

For clinicians facing diagnostically challenging cases, the result is a broader, more comprehensive approach to pathogen identification.

NeXGen™ Fungal/AFB: Bringing greater clarity to complex cases

The NeXGen™ Fungal/AFB assay is designed to detect and identify 534 fungal genus/species targets and 154 acid-fast bacterial genus/species targets from whole blood and bronchoalveolar lavage samples.

The assay’s broad scope may be particularly valuable when:

  • Clinical symptoms are nonspecific.
  • Traditional testing has been inconclusive.
  • Low-burden infections are suspected.
  • Multiple pathogens are under consideration.
  • Clinicians require species-level identification to support individualized treatment decisions.

By evaluating hundreds of fungal and AFB targets simultaneously, NeXGen™ may help clinicians move from a broad list of possibilities toward a more precise understanding of disease causation.

From identifying pathogens to understanding immune response

Many healthcare providers know Eurofins Viracor through its longstanding leadership in transplant infectious disease diagnostics. Today, the company’s approach extends beyond traditional pathogen detection alone.

The NeXGen™ portfolio represents one dimension of that strategy: helping clinicians identify potential infectious causes when the diagnosis remains uncertain. Equally important is understanding how a patient’s immune system responds once an infection has been identified.

Eurofins Viracor’s inSIGHT™ immune functional assays for CMV, EBV, and (their new) BK virus provide information about pathogen-specific cellular immune responses, offering clinicians additional insight into a patient’s ability to respond to these clinically important viral infections. Together, these tools support a more comprehensive view of both infection and host response.

In many ways, these technologies address two critical clinical questions:

What pathogen may be present? And how effectively can the patient respond to it?

This complementary approach reflects Eurofins Viracor’s broader commitment to serving transplant, infectious disease, oncology, hematology, and other specialty providers managing patients with complex diagnostic and immune-monitoring needs.

A new chapter in infectious disease diagnostics

As infectious disease management becomes increasingly personalized, clinicians need tools that deliver more than isolated data points. They need technologies capable of helping transform uncertainty into clarity, suspicion into specificity, and diagnostic questions into actionable insights.

About the author

Kevin Foth, MT (ASCP), MBA-IB

Senior Clinical Product Manager

Viracor

Back to top